alan list: is luspatercept a new option for patients with mds?
Published 5 years ago • 2.4K plays • Length 4:48Download video MP4
Download video MP3
Similar videos
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
6:32
luspatercept reduces transfusion burden in mds-related anemia: medalist results
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
4:36
commands: luspatercept versus epoetin alfa in lr-mds-associated anemia - results & caveats
-
1:15
luspatercept for the treatment of patients with lower-risk mds and esa failure
-
3:40
no sound reblozyl® (luspatercept-aamt) for anaemia
-
7:32
does luspatercept reduce blood transfusions in mds patients?
-
15:29
current advances in thalassaemia: reblozyl (luspatercept) | prof. antonio piga
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
6:34
alan f. list: the medalist trial
-
6:31
results from the medalist trial for patients with anaemia in mds
-
0:56
luspatercept for mds-associated anemia
-
1:06
commands trial: luspatercept vs epoetin alfa in lower-risk mds
-
3:54
results of medalist: luspatercept reduces transfusion burden in mds
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
1:32
novel drug targets for mds
-
14:41
luspatercept compared with other available therapies for mf
-
2:26
ace-536-mf-001 update: luspatercept for the treatment of anemia in myelofibrosis
-
7:14
phase iii medalist trial of luspatercept for mds
-
4:35
lower-risk mds in 2021: luspatercept, imetelstat & roxadustat
-
3:38
a new set of treatment options for low-risk mds